Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A bioequivalence and food-effect study comparing two tablet formulations of tebipenem pivoxil hydrobromide (TBPM-PI-HBr) in healthy adult subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A: TBPM-PI-HBr (Reference - fasted) | Experimental | 600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions. |
|
| B: TBPM-PI-HBr (Test - fasted) | Experimental | 600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fasted conditions. |
|
| C: TBPM-PI-HBr (Test - fed) | Experimental | 600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr administered at Hour 0 on Day 1, under fed conditions. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference | Drug | 600 mg (2 x 300 mg tablets) clinical study drug product batch TBPM-PI-HBr. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Area under the curve extrapolated to infinity (AUC0-∞). | 24h (Day 2) post dose (Arms: A, B, C) | |
| Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t). | 24h (Day 2) post dose (Arms: A, B, C) | |
| Maximum plasma concentration (Cmax). | 24h (Day 2) post dose (Arms: A, B, C) |
| Measure | Description | Time Frame |
|---|---|---|
| Time to the maximum plasma concentration (Tmax). | 24h (Day 2) post dose (Arms: A, B, C) | |
| Terminal elimination half-life (t½). | 24h (Day 2) post dose (Arms: A, B, C) | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| David Melnick | Spero Therapeutics | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Facility | Tempe | Arizona | 85283 | United States |
Not provided
Open-Label, Randomized, Single-Dose, Semi-Replicate, 4-Period, Crossover
Not provided
Not provided
Not provided
Not provided
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test | Drug | 600 mg (2 x 300 mg tablets) registration drug product batch TBPM-PI-HBr. |
|
| Apparent total body clearance (CL/F) |
| 24h (Day 2) post dose (Arms: A, B, C) |
| Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F). | 24h (Day 2) post dose (Arms: A, B, C) |
| Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug. | ECG, Clinical Laboratories, Vitals Signs and Physical Exams will be used as a safety measure to detect any AEs. | 12 to 14 days after the last dose of study drug |
| Area under the curve extrapolated to infinity (AUC0-∞). | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |
| Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t). | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |
| Maximum plasma concentration (Cmax). | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |
| Time to the maximum plasma concentration (Tmax). | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |
| Terminal elimination half-life (t½). | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |
| Apparent total body clearance (CL/F) | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |
| Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F). | TPBM PK parameters following administration of the TBPM-PI-HBr Test tablet under fasted and fed conditions. | 24h (Day 2) post dose (Arms: B, C) |